首页> 外国专利> Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials

Medicament used to reduce risk of e.g. heart disease and urinary tract disease, comprises 5-methyl-(6S)-tetrahydrofolate, estrogen and/or gestagene, vitamin B6 and/or vitamin B2 and auxiliary or carrier materials

机译:用于降低患病风险的药物心脏病和尿路疾病,包括5-甲基-(6S)-四氢叶酸,雌激素和/或孕激素,维生素B6和/或维生素B2以及辅助或载体材料

摘要

Medicament (A) comprises 5-methyl-(6S)-tetrahydrofolate, one or more estrogen and/or gestagene, optionally vitamin B6 and/or vitamin B2 and auxiliary or carrier materials. Independent claims are included for: (1) a kit comprising at least 20 daily dose units of (A), at least a daily dose unit containing 5-methyl-(6S)-tetrahydrofolate and optionally vitamin B6 and/or vitamin B2 (where the amount of all the dose units in the kit is at least 28, and the dose unit of (A) is administrated first and subsequently the dose unit containing 5-methyl-(6S)-tetrahydrofolate); and (2) preparation of the medicament which comprising granulating 5-methyl-(6S)-tetrahydrofolate. ACTIVITY : Cardiant; Uropathic; Cytostatic; Antiinfertility; Tests are described, but no results are given. MECHANISM OF ACTION : None given.
机译:药物(A)包含5-甲基-(6S)-四氢叶酸,一种或多种雌激素和/或孕激素,任选地维生素B6和/或维生素B2以及辅助或载体材料。包括以下独立权利要求:(1)试剂盒,其中包含(A)的至少20个日剂量单位,至少包含5-甲基-(6S)-四氢叶酸和任选的维生素B6和/或维生素B2的日剂量单位(其中试剂盒中所有剂量单位的数量至少为28,并且首先给药(A)的剂量单位,然后先给药含有5-甲基-(6S)-四氢叶酸的剂量单位); (2)制备包括将5-甲基-(6S)-四氢叶酸制粒的药物。活动:Cardiant;尿毒症;细胞抑制抗不孕症;描述了测试,但未给出结果。作用机理:未给出。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号